- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01086618
Chemotherapy With or Without Surgery in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery
A Randomized Trial of Initial Surgery in Advanced Asymptomatic Colorectal Cancer Patients Receiving Chemotherapy for Metastatic Disease
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy after surgery may kill any tumor cells that remain after surgery. It is not yet known whether chemotherapy is more effective when given alone or together with surgery in treating patients with colorectal cancer.
PURPOSE: This randomized phase II/III trial is studying how well chemotherapy works and compares it with surgery followed by chemotherapy in treating patients with metastatic colorectal cancer that can not be removed by surgery.
Studieoversikt
Status
Forhold
Detaljert beskrivelse
OBJECTIVES:
- To determine whether overall survival is improved in patients with asymptomatic, unresectable metastatic colorectal cancer treated with chemotherapy alone versus surgery followed by chemotherapy.
OUTLINE: This is a multicenter study. Patients are randomized to 1 of 2 treatment arms.
- Arm I (control arm): Patients receive systemic chemotherapy according to standard local practice. Patients who develop symptoms from their primary tumor receive treatment as required including surgery, if indicated.
- Arm II (experimental arm): Patients undergo surgery at the discretion of the surgeon. Beginning 8 weeks after completion of surgery, patients receive chemotherapy according to standard local practice.
Patients complete quality-of-life questionnaires (EQ-5D) at baseline and then periodically during and after completion of study treatment.
After completion of study treatment, patients are followed every 3 months.
Peer Reviewed and Funded or Endorsed by Cancer Research UK
Studietype
Registrering (Forventet)
Fase
- Fase 2
- Fase 3
Kontakter og plasseringer
Studiesteder
-
-
England
-
London, England, Storbritannia, NW1 2BU
- University College Hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
DISEASE CHARACTERISTICS:
Histologically or cytologically confirmed colorectal cancer
- Metastases which are unresectable at presentation
- No known unresectable primary tumor on CT/MRI scan
Primary tumor does not require immediate or emergency intervention including surgery, radiotherapy, laser, or stenting
- Patients who are treated with colonic stents are eligible
- No unequivocal extensive peritoneal metastases
PATIENT CHARACTERISTICS:
- WHO performance status 0-1
- Must be fit for systemic chemotherapy and surgery
- Hemoglobin > 10.0 g/dL
- WBC > 3.0 x 10^9/L
- Platelet count > 100 x 10^9/L
- Bilirubin < 25 μmol/L
- GFR > 50 mL/min
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 3 months (female) or up to 2 months (male) after completion of study therapy
- No history of malignant disease within the past 5 years except for nonmelanomatous skin cancer or carcinoma in situ of the cervix
- No serious medical co-morbidity (e.g., uncontrolled inflammatory bowel disease, uncontrolled angina, recent [within the past 6 months] myocardial infarction, or another serious medical condition) judged to compromise ability to tolerate chemotherapy and/or surgery
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- Concurrent participation in a trial of chemotherapy, if eligible, allowed
- Concurrent short-course radiotherapy for operable rectal cancer allowed
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
Hva måler studien?
Primære resultatmål
Resultatmål |
---|
Accrual rate in months 10 to 12 (phase II)
|
Overall survival for ≥ 2 years (phase III)
|
Sekundære resultatmål
Resultatmål |
---|
Livskvalitet (fase III)
|
Morbidity of surgery (phase II)
|
Percentage of patients who receive chemotherapy following surgery (must be over 80%) (phase II)
|
Morbidity of chemotherapy and surgery (phase III)
|
Economic evaluation (phase III)
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Austin Obichere, MD, University College London Hospitals
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- CDR0000667364
- UCL-08/0079
- UCL-ISAAC
- ISRCTN10963271
- EU-21008
- CRUK-C32436/A10431
- EUDRACT-2008-005911-16
- MREC-09/H1102/60
- NCRI-UCL-08/0079
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Tykktarmskreft
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeMetastatisk kolorektalt karsinom | Trinn IV tykktarmskreft AJCC v8 | Stage IVA tykktarmskreft AJCC v8 | Stage IVB tykktarmskreft AJCC v8 | Stage IVC Colorectal Cancer AJCC v8Forente stater
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)FullførtTrinn IV tykktarmskreft AJCC v7 | Stage IVA kolorektal kreft AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Kolorektalt adenokarsinom | RAS Wild TypeForente stater
-
Ning JinAktiv, ikke rekrutterendeMetastatisk kolorektalt karsinom | Trinn IV tykktarmskreft AJCC v8 | Stage IVA tykktarmskreft AJCC v8 | Stage IVB tykktarmskreft AJCC v8 | Stage IVC Colorectal Cancer AJCC v8Forente stater
-
University of California, San FranciscoMerck Sharp & Dohme LLCFullførtTrinn IV tykktarmskreft AJCC v7 | Stage IVA kolorektal kreft AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Mikrosatellitt stabil | Trinn III tykktarmskreft AJCC v7 | Trinn IIIB tykktarmskreft AJCC v7 | Stage IIIC tykktarmskreft AJCC v7 | Mismatch Repair Protein dyktigForente stater
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)FullførtTrinn IV tykktarmskreft AJCC v7 | Stage IVA kolorektal kreft AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Tilbakevendende kolorektalt karsinom | Metastatisk karsinom i leverenForente stater
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)FullførtTrinn IV tykktarmskreft AJCC v7 | Stage IVA kolorektal kreft AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Metastatisk karsinom i leveren | Resektabel masseForente stater
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); Genentech, Inc.Aktiv, ikke rekrutterendeTrinn IV tykktarmskreft AJCC v7 | Stage IVA kolorektal kreft AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Metastatisk malignt fast neoplasma | Ikke-opererbar fast neoplasma | BRAF NP_004324.2:p.V600X | KRAS wt AllelForente stater
-
M.D. Anderson Cancer CenterRekrutteringMetastatisk malign neoplasma i leveren | Metastatisk kolorektalt karsinom | Trinn IV tykktarmskreft AJCC v8 | Stage IVA tykktarmskreft AJCC v8 | Stage IVB tykktarmskreft AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Resektabelt kolorektalt karsinomForente stater
-
Chloe Atreya, MD, PhDMerck Sharp & Dohme LLC; MedPacto, Inc.RekrutteringMetastatisk malign neoplasma i leveren | Trinn IV tykktarmskreft AJCC v8 | Stage IVA tykktarmskreft AJCC v8 | Stage IVB tykktarmskreft AJCC v8 | Stage IVC Colorectal Cancer AJCC v8Forente stater
-
National Cancer Institute (NCI)Aktiv, ikke rekrutterendeStage IVA kolorektal kreft AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Tilbakevendende kolorektalt karsinom | Trinn IIIA tykktarmskreft AJCC v7 | Trinn IIIB tykktarmskreft AJCC v7 | Stage IIIC tykktarmskreft AJCC v7 | Solid neoplasmaForente stater, Canada
Kliniske studier på terapeutisk konvensjonell kirurgi
-
Diakonessenhuis, UtrechtRekrutteringLivskvalitet | Søvnapné, obstruktivNederland
-
Boston Medical CenterHar ikke rekruttert ennåRusmisbruksforstyrrelser | Psykisk helseproblemForente stater
-
Babes-Bolyai UniversityAktiv, ikke rekrutterendeREThink Game | Behandling som vanligRomania
-
Royal Surrey County Hospital NHS Foundation TrustUkjentEggstokkreft | Egglederkreft | Peritoneal kreft | Neoplasma i eggstokkene | Ovarial neoplasma epitelialStorbritannia
-
University of Colorado, DenverRekrutteringForbedret restitusjon etter operasjon | Gynekologisk sykdomForente stater
-
Universidade Federal de Sao CarlosFullført
-
ARCAGY/ GINECO GROUPRekrutteringEggstokkreft stadium IIIC | Eggstokkreft Stadium IV | Eggstokkreft stadium IIIbFrankrike
-
Bournemouth UniversityStryker Orthopaedics; Nuffield Health Bournemouth; Orthopaedic Research InstituteRekruttering
-
Ayşe ARIKAN DÖNMEZHar ikke rekruttert ennåDemens | Virtuell virkelighet | Utdanning | SykepleierstudenterTyrkia
-
Grupo Español de Rehabilitación MultimodalInstituto de Salud Carlos III; Instituto de Investigación Sanitaria AragónRekruttering